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Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention.
However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular
events. Although many genetic and nongenetic factors are known, great portion of clopidogrel variable platelets reactivity
remain unexplained which challenges the personalization of clopidogrel therapy. Current methods for clopidogrel personalization
include CYP2C19 genotyping, pharmacokinetics, and platelets function testing. However, these methods lack precise prediction
of clopidogrel outcome, often leading to insufficient prediction. Pharmacometabolomics which is an approach to identify
novel biomarkers of drug response or toxicity in biofluids has been investigated to predict drug response. The advantage of
pharmacometabolomics is that it does not only predict the response but also provide extensive information on the metabolic
pathways implicated with the response. Integrating pharmacogenetics with pharmacometabolomics can give insight on unknown
genetic and nongenetic factors associated with the response. This review aimed to review the literature on factors associated with
the variable platelets reactivity response to clopidogrel, as well as appraising current methods for the personalization of clopidogrel
therapy. We also aimed to review the literature on using pharmacometabolomics approach to predict drug response, as well as
discussing the plausibility of using it to predict clopidogrel outcome.
1. Introduction
Clopidogrel is a second-generation thienopyridine antiplate-
let drugwhich exerts its effect by the inhibition of the platelet’s
purinergic receptor P2Y12 preventing adenosine diphosphate
(ADP) from stimulating it. Clopidogrel is crucial drug for
patients enduring high platelets reactivity such as coronary
artery disease (CAD), acute coronary syndrome (ACS), and
stroke. Some patients may require invasive therapy such as
percutaneous coronary intervention (PCI) with stent placed
in the occluded artery to ensure enough blood flow through it
[1]. PCI patients have to take loading dose of clopidogrel prior
to procedure followed by postprocedure dual antiplatelet
therapy (DAPT) of low dose aspirin and clopidogrel for dura-
tion up to 12monthsbased onstent typeandriskassessment [2].
This DAPT therapy is pivotal to prevent stent thrombosis
(ST) and recurrence of ischemic events after PCI. However,
some patients may suffer from attenuated platelets inhibition
to clopidogrel or clopidogrel high on treatment platelets
reactivity (HTPR) which hinders achieving the optimum
outcome of DAPT. There are genetic and nongenetic factors
contributing to clopidogrel HTPR, however, often challeng-
ing therapeutic outcome prediction [3]. Current methods
of predicting clopidogrel response do not predict clopido-
grel therapeutic outcome adequately.Therefore, investigating
new approaches to assess clopidogrel response can help
to achieve the desired outcome after PCI. In this review,
we aimed to review the literature on clopidogrel variable
platelets reactivity and appraise currentmethods to assess the
clopidogrel therapeutic outcome.We also aimed to review the
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literature on new approaches such as pharmacometabolomics
and integrative pharmacometabolomics-pharmacogenetics
in assessing clopidogrel therapeutic outcome.
2. Clopidogrel Bioactivation and
Clopidogrel HTPR
Clopidogrel is an oral drug which has oral bioavailability of
50% and the maximum peak concentration will be observed
within 1 to 2 hours after the administration of the loading
dose (600mg) [4, 5].The half-life of clopidogrel is from 7 to 8
hours [6]. Almost 50% of clopidogrel dose is excreted in the
urine and 46% in the faeces [7]. Of the oral dose, approxi-
mately 85% is hydrolysed by esterases into inactivemetabolite
while the remaining 15% will be activated by the hepatic
cytochrome P450 (CYP
450
) enzymes to the active metabolite
through two steps of bioactivation [8]. The hepatic CYP
450
enzymes which are involved in the bioactivation process of
clopidogrel include the CYP1A2, CYP2B6, and CYP2C19 in
the first step and the CYP2B6, CYP2C9, CYP3A4/5, and
CYP2C19 in the second step [9–11]. The CYP2C19 enzyme
plays vital role in the two bioactivation steps of clopidogrel
by participating with 44.9% in the first step and 20.6% in the
second step [9, 12]. The CYP3A4 has an essential role in the
second step by participating with 39.8% [9]. Clopidogrel has
minimum neutropenic side effect compared to ticlopidine
(first-generation thienopyridine) [13]. The main side effects
of clopidogrel are bleeding, gastrointestinal disorders, and
rash, as well as other side effects such as hepatotoxicity and
thrombotic thrombocytopenic purpura, albeit they are rare.
Therefore, it is well tolerated by patients.
Patients variable platelets inhibition while on clopidogrel
was first reported by Ja¨remo et al. in 2002 [14]. In that
study, five out of the eighteen PCI patients had weak platelets
inhibition in response to clopidogrel loading dose of 300mg.
Since it was first reported, clopidogrel HTPR has been largely
documented. It was found to be affecting 15–40% of the
patients [4, 15, 16]. Clopidogrel HTPR is associated with poor
outcome after PCI. Matetzky and colleagues indicated an
association between clopidogrel HTPR and the risk of cardiac
events’ recurrence among 60 ACS patients undergoing PCI
who had taken loading dose of 300mg followed by daily dose
of 75mg for three months [17]. Substantiating these findings,
Geisler et al. (2006) indicated that the primary end point of
myocardial infarction, stroke, and death were significantly
increased in clopidogrel HTPR patients who were followed
up for three months after the PCI [18].
3. Genetic Factors Contributing
to Clopidogrel HTPR
There are several identified genetic variabilities which con-
tribute to clopidogrel HTPR. In fact, clopidogrel variable
platelets reactivity is highly heritable [19]. As clopidogrel
undergoes intestinal absorption, bioactivation by the hepatic
CYP
450
enzymes, and deactivation by esterases, this process
might be affected by several genetic variabilities. Genetic
variabilities which may interfere with clopidogrel vari-
able platelets reactivity include the polymorphisms of the
CYP2C19 [19], theCYP3A4/5 [20], theCYP2C9 [21], the ATP-
Binding Cassette Subfamily B Member 1 (ABCB1) [22], the
Paraoxonase-1 (PON1), the Carboxyl Esterase 1 (CES1) [23],
and the genetic polymorphism of the P2Y12 receptors [24].
There are 57 active genes of the CYP
450
enzymes and
58 pseudogenes in the human genome [25]. For most of
the clinically relevant CYP
450
enzymes, they are highly
affected by genetic polymorphisms [26]. The CYP
450
genetic
polymorphisms could interfere with gene transcription, gene
expression regulation, protein translation, and affinity to
substrate [26, 27]. Among the CYP
450
reported genetic poly-
morphisms, the CYP2D6, CYP2C9, and the CYP2C19 were-
extensively studied and reported, respectively [28]. Of all
studied CYP
450
genetic polymorphisms, the CYP2C19 poly-
morphisms were found to be highly associated with clopido-
grel variable response, particularly that the enzyme is invol-
ved in the two bioactivation steps.
3.1. CYP2C19 Polymorphisms. The CYP2C19 enzyme plays
substantial role in the metabolism and bioactivation of
drugs such as proton pump inhibitors (PPIs) (omeprazole,
lansoprazole, and pantoprazole), selective serotonin reuptake
inhibitors (citalopram and sertraline), tricyclic antidepres-
sant (imipramine and amitriptyline), phenytoin, and clopido-
grel. The CYP2C19 enzyme is known by its classical reaction;
the (S)-mephenytoin 4󸀠-hydroxylation [29]. The gene of the
CYP2C19 is highly polymorphic with more than 25 alleles
having variable enzymatic activity levels [30]. The star one
allele (∗1) is the normal or “wild type,” a homozygous form
of this allele’s (∗1/∗1) phenotypes for the gained full function
of the enzyme. Of all polymorphic alleles of the CYP2C19,
two reduced functions alleles were identified as (∗2) and
(∗3) alleles have been extensively studied. De Morais et al.
(1994) had found that they cause poor metabolism of (S)-
mephenytoin metabolism among Japanese [29]. Both the
CYP2C19∗2 and CYP2C19∗3 alleles are single nucleotide
polymorphism (SNP) of guanine (G) to adenine (A) present
at nucleotide 681 in exon 5 and at nucleotide 636 in exon
4, respectively [29, 31]. The CYP2C19∗2 causes aberrant
splice site leading to the formation of stop codon which
produces truncated, nonfunctional protein which is cat-
alytically inactive [29]. The CYP2C19∗3 causes premature
termination codonwhich leads to the formation of truncated,
nonfunctioning protein which is also catalytically inactive
[31]. The CYP2C19∗17 is another allele of the CYP2C19
which is associated with increased gene transcription that
leads to increased activity of the enzyme [32]. Clinically,
individuals are classified into extensive metabolizers (EM),
intermediate metabolizers (IM), poor metabolizers (PM),
and ultrametabolizer (UM) of drugs based on their CYP2C19
genotype [10]. Table 1 shows subjects’ CYP2C19 genotype
and their CYP2C19 phenotype. The presence of at least one
allele of the CYP2C19∗2 is observed in 15–30%, 33–40%,
and 40–50% of the Caucasians, African Americans, and
Asians, respectively [33–35]. However, the CYP2C19∗3 allele
is present in less than 1% of both Caucasians and African
Americans and 7% of Asians.
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Table 1: Phenotype metabolising classes based on CYP2C19
genotype∗.
Phenotype Examples ofthe genotype Enzyme activity
Ultrarapid metabolizer
(UM)
∗1/∗17 Normal or increased
enzyme activity∗17/∗17
Extensive metabolizer
(EM) ∗1/∗1 Normal enzyme activity
Intermediate metabolizer
(IM)
∗1/∗2
Intermediate enzyme
activity∗1/∗3
∗2/∗17
Poor metabolizer (PM)
∗2/∗2
Low or absent enzyme
activity∗3/∗3
∗2/∗3
∗This table is adapted and modified with permission from the publisher.
Original source: Scott et al. (2013) [10]. Copyright© (2013). Published by
Wiley. All rights reserved.
The importance of the CYP2C19 loss of function (LoF)
alleles, CYP2C19∗2 and CYP2C19∗3 effect on clopidogrel
response, stems not only from their association with clopi-
dogrel HTPR, but also from their association with poor ther-
apeutic outcome [36]. Poor metabolizers (based on CYP2C19
genotype) had lower plasma concentration of clopidogrel
active metabolite [21]. Shuldiner and colleagues had found
significant association between the CYP2C19∗2 genotype
and both the low platelets’ inhibition to clopidogrel and the
increase of cardiovascular events among PCI patients [19].
Mega and colleagues reported low level of the active metabo-
lite of clopidogrel, reduced platelets inhibition to clopidogrel,
and higher risk of ischemic events among patients who are
carriers of theCYP2C19 LoF alleles [34].These results, as well
as other findings, encouraged the United States (US) Food
andDrug Administration (FDA) to issue labelled warning on
clopidogrel box recommending the genotyping of CYP2C19
in order to prevent recurrence of cardiovascular events [12].
3.2. Other Genetic Polymorphisms. Apart from the CYP2C19
polymorphisms, the current literature is consistent about
the limited effect of other CYP genetic polymorphisms on
the exposure to clopidogrel active metabolite and platelets
inhibition. Nevertheless, some controversy exists about some
genetic variants. Brandt and colleagues investigated the effect
of CYP polymorphisms on the exposure to clopidogrel active
metabolite and platelets reactivity [21]. They indicated that
the presence of the CYP2C19 or the CYP2C9 LoF variants
was associated with reduced exposure to clopidogrel active
metabolite and decreased platelets inhibition. However, the
CYP1A2, theCYP2B6, theCYP3A4, andCYP3A5 did not have
any effect. Park and colleagues indicated similar findings;
however, they did not investigate the effect of CYP2C9 vari-
ants [37]. Although several studies showed that the CYP2B6
polymorphism did not have an effect, a study indicated that
carriers of the CYP2B6 had lower exposure to clopidogrel
active metabolite and lower platelets inhibition compared
to noncarriers [34]. Although several studies suggested
that the association between the CYP3A4 and the CYP3A5
polymorphisms and clopidogrel HTPR is not significant
[34, 37–39], others indicated significant association between
them [11, 20, 40]. This might be due to the major role of
the CYP3A4 and CYP3A5 enzymes in the second step of
clopidogrel bioactivation whichmay substantiate the effect of
their genetic polymorphisms on clopidogrel exposure.
TheABCB1 gene is the coding gene for the P-glycoprotein
multidrug resistance-1 (MDR1) intestinal transporter, a mod-
ulator of clopidogrel absorption [41]. A genetic polymor-
phism of theABCB1 causes reduced absorption of clopidogrel
[22]. Simon et al. (2009) found that ACS patients who were
treated with clopidogrel and were carriers of the two variants
alleles of the ABCB1 had higher rate of cardiovascular events
at one year of follow-up [35]. Similarly, Mega et al. (2010)
indicated that the ABCB1 polymorphism is significantly
associated with the risk of deaths due to cardiovascular
events or stroke among ACS patients treated with clopidogrel
in the “Trial to Assess Improvement in the Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel-
Thrombolysis in Myocardial Infarction” (TRITON-TIMI 38)
trial [42]. However, other studies failed to indicate the same
findings [19, 41].
As the majority of clopidogrel dose is being metabolized
by the CES1 enzyme, a reduced function genetic polymor-
phism of this enzyme can lead to variable response to clopi-
dogrel [23, 43]. Zhu et al. (2013) found that the inhibition of
CES1 enzyme and the CES1 reduced function genetic poly-
morphisms are associated with the reduced hydrolytic
metabolism of clopidogrel and the increased concentrations
of clopidogrel active metabolite in an in vitro model [43].
Lewis et al. (2013) studied the effect of the CSE1 reduced
function genetic variant on clopidogrel exposure and platelets
inhibition among 566 healthy volunteers from the Amish
“Pharmacogenomics of Anti-Platelet Intervention” (PAPI)
study. The study revealed that the level of clopidogrel active
metabolite is significantly higher among carriers of the
reduced function allele [23]. In addition, the platelets inhi-
bition measured by an ADP-stimulated platelet aggregation
was higher in those whowere carriers of the reduced function
allele. Such findings suggest that the CES1 reduced function
genetic polymorphisms may play vital role in the variable
platelets inhibitory effect of clopidogrel. Thus, it would be
valuable for future investigations to test this role on patients’
outcome.
The PON1 is an esterase enzyme which is synthesized in
the liver [44].The PON1, full enzymatic activity, is associated
with atheroprotective effect which can be due to its role in
enhancing an increased level of the high-density-lipoprotein
(HDL) [45–47]. Therefore, patients who were carriers of the
PON1 lower activity genetic polymorphism were found to
be having an increased oxidative stress and higher risk of
cardiovascular events [45]. A presumed role of the PON1
enzyme in the metabolism of clopidogrel and its responsive-
ness stemmed controversy [46]. Bouman et al. (2011) used
an in vitro metabolomics profiling which indicated that the
PON1 is imperative enzyme in the hydrolytic cleavage of the
intermediatemetabolite of clopidogrel (2-oxo-clopidogrel) to
the active metabolite of clopidogrel [44]. Accordingly, the
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PON1 genetic variant of lower enzymatic activity causes lower
level of clopidogrel active metabolite. Based on their find-
ings, they conducted a case-cohort study on CAD patients
undergoing PCI and a further prospective replication study
on another independent sample of 1982 patients with ACS
[44]. Both the case-cohort and the prospective replication
studies concluded that there was an association between
the genetic variant of PON1 and the pharmacokinetics, the
pharmacodynamics, and therapeutic outcome of clopidogrel
[44]. These findings were challenged by other studies which
indicated that this association is not significant [46, 47]. In
fact, the effect of PON1 genetic variant on the therapeutic
outcome was attributed to the association between this
variant and the risk of developing cardiac events [46, 47].
The data on the effect of the P2Y12 genetic variants on
clopidogrel response is dialectical. Some studies supported
an effect of the P2Y12 polymorphism on platelets activation
and clopidogrel response [24, 48, 49], while others refuted
this effect [50, 51] or indicated a synergistic effect of it, if
coexisted with other genetic variabilities such as CYP2C19
and MDR1 [52, 53]. There are two haplotypes of the P2Y12
gene (H1 and H2) where the H2 represents a gain-of-
function haplotype of the receptor which might cause an
increase in atherothrombosis and interfere with the response
to clopidogrel [48]. The homozygous haplotype of H2 was
found to be associated with clopidogrel HTPR [24].
Although the data are conflicting, it could be inferred
from current literature that, except for the CYP2C19, most
of the investigated genetic polymorphisms have weak or
insignificant effect on the clopidogrel exposure and platelets
inhibition. However, the coexistence of polymorphisms may
have significant effect on platelets inhibition. In fact, the
possession of the CYP2C19 polymorphism and other poly-
morphisms can lead to synergistic effect. For instance, Mega
and colleagues concluded that PCI patients who have both
ABCB1 and CYP2C19 genetic variants may be vulnerable to
the recurrence of cardiac events while they are on clopidogrel
treatment [42]. Similarly, some studies indicated that coexis-
tence ofCYP2C19 andP2Y12 receptor genetic polymorphisms
has higher effect on clopidogrel responsiveness and the
clinical outcome than single polymorphism [52, 53]. Fur-
thermore, the use of a drug with enzymatic inhibitory effect
in patients who have polymorphism of reduced enzymatic
activity for the same enzyme may lower platelets inhibition
to clopidogrel. Park et al. (2013) indicated that patients on
calcium channel blockers (CCBs) who were carriers of the
CYP3A4 (IVS 10 + 12) A allele (GA and AA) had higher
platelets reactivity while on clopidogrel compared to the
noncarriers-wilt type (GG) [54].
4. Nongenetic Factors Contributing
to Clopidogrel HTPR
Other multiple nongenetic factors interfere with clopidogrel
response. Clinical factors such as concomitant diseases, drug-
drug interaction, patient’s compliance, obesity, and age are
known to influence clopidogrel response. In addition, lifestyle
factors such as smoking and diet can also affect the response.
The presence of comorbid condition such as type 2 dia-
betes mellitus (T2-DM) increases platelets reactivity in CAD
patients which may cause poor therapeutic outcome [55].
In fact, T2-DM patients were found to endure clopidogrel
HTPR while on DAPT [56]. However, the interindividual
clopidogrel variable platelets reactivity among CAD patients
with T2-DM might be due to the concomitance of genetic
or nongenetic factors [55, 57]. It had been suggested that
the administration of high maintenance dose of clopidogrel
or more potent P2Y12 antagonists such as prasugrel can be
used to overcome the clopidogrel HTPR in T2-DM [58].
Similar to T2-DM, patients suffering from chronic kidney
disease (CKD) had reduced platelets inhibition to clopidogrel
[59]. The decreased platelets inhibition in CKD patients was
indicated for both clopidogrel and aspirin in patients on
DAPT [60]. This reduced response is suggested to be due to
the increased baseline platelets reactivity inCKDpatients [60,
61]. The association between renal insufficiency and the risk
of death and cardiac events after PCI is well established [62].
However, inconsistent data is available, in terms of the risk of
bleeding, among PCI patients with underlying CKD [63, 64].
Noteworthily, the concomitance of comorbidities such as T2-
DMwithmoderate to severe CKDwas found to be associated
with high platelets reactivity inCADpatients onDAPTwhich
might lead to high frequency of poor outcome in this group
of patients [65]. Recently, in Japanese population, it has been
found that CKD is an independent predictor of PCI outcome,
regardless of theCYP2C19 genetic polymorphism status of the
patient [66].
As clopidogrel is bioactivated by the CYP
450
enzymes, it
can be prone to drug-drug interactions, particularly drugs
interfering with the CYP
450
system.The PPIs are metabolized
by the CYP
450
enzymes; therefore, they might interact with
clopidogrel [67]. However, the data on the extent of PPIs
interact with clopidogrel remain controversial which suggests
further investigation. In fact, the PPIs inhibit the CYP2C19
enzyme which might reduce the bioactivation of clopidogrel
to its active metabolite [67, 68]. Accordingly, this could
decrease the antiplatelet effect of clopidogrel which may
increase cardiovascular events [68].ThePPIsmaynot interact
to the same extentwith clopidogrel [69]. In otherwords, some
studies concluded that omeprazole was associated with the
reduced antiplatelet effect of clopidogrel, while esomeprazole
and pantoprazole were not [68, 69]. Similarly, lipophilic
statins antihyperlipidemic drugs such as atorvastatin and
simvastatin were reported to inhibit the antiplatelet effect of
clopidogrel [70–72]. These statins interfere with the CYP3A4
enzyme [71]. Thus, it can mitigate the antiplatelet effect of
clopidogrel. However, the preventive effect of statins by red-
ucing lipid levels can halt cardiovascular events which might
happen consequently to the reduced antiplatelet effect of
clopidogrel [70]. Similar to the effect of statins albeit with
some controversy in the literature, some drugs such as
some CCBs, erythromycin, troleandomycin, and ketocona-
zole inhibit the CYP3A4 enzyme which will reduce the level
of the clopidogrel activemetabolite which can lead to reduced
antiplatelet effect of clopidogrel [68, 73]. However, the data
from some studies did not support this suggestion [74, 75].
For instance, the “Clopidogrel for the Reduction of Events
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During Observation” (CREDO) trial indicated that the con-
comitance use of the CCBs does not reduce the efficacy of
clopidogrel and there was no evidence of interaction between
them [75]. Anticoagulant drugs such as coumarin derivatives
may also interfere with platelets inhibition by clopidogrel.
Sibbing et al. (2010) indicated a significant reduction in
the platelets’ inhibitory effect of clopidogrel among patients
concomitantly taking phenprocoumon when compared to
those who are not taking phenprocoumon. This could be
because of the interference with the capacities of the CYP3A4
and the CYP2C9 enzymes which are the main metabolizing
enzymes of the phenprocoumon [76]. Sulfonylureas oral
hypoglycaemic drugs may also reduce platelets inhibitory
effect of clopidogrel [77].This could be due to the interference
with CYP2C9 enzyme, as well [77, 78]. On the other hand,
there are also drugswhich can increase or decrease the level of
clopidogrel activemetabolite by the inhibition or induction of
the CES1 enzyme [43].Thismight lead to clopidogrel variable
platelets reactivity [79]. For instance, the phenobarbital, the
dexamethasone, and the polycyclic aromatic hydrocarbons
are drugswhich can interferewith the activity of CES1 leading
to variable levels of clopidogrel active metabolite [79].
Patient’s compliance is crucial for achieving optimum
therapeutic outcome. It has been found that noncompliance
contributes significantly to clopidogrel HTPR [80]. Age, lipid
levels, and body mass index (BMI) have been found to define
nearly 22% of clopidogrel HTPR [19]. An age of more than 65
years old is associated with reduced platelets inhibitory effect
of clopidogrel [81]. Furthermore, food, drinks, and smok-
ing may interfere with clopidogrel response. For example,
grapefruit can lower platelets inhibitory effect of clopidogrel
which could be due to the interference with CYP
450
isoforms
[82]. In contrast, caffeinated drinks can increase platelets’
inhibitory effect of clopidogrel [83]. Similarly, smoking was
found to increase platelets’ inhibitory effect of clopidogrel
[84]. Smoking increases the bioactivation of clopidogrel to
its active metabolite by the induction of the CYP1A2 and
the CYP2B6 enzymes which are involved in the first step of
the bioactivation of clopidogrel. This will increase platelets
inhibition effect of clopidogrel.
5. Personalization of Clopidogrel Therapy
It could be clearly understood that there are multifactorial
genetic and nongenetic factors which interfere with clopi-
dogrel variable platelets reactivity as depicted in Figure 1
[85]. However, these known factors failed to explain great
portion of the variable platelets reactivity of clopidogrel [86].
For instance, Frelinger et al. (2013) assessed the pharma-
cokinetics and the pharmacodynamics of 75mg daily dose
of clopidogrel, administered by 160 healthy subjects for 9
days. The 160 subjects were free from nicotine for 6 weeks,
prescription drugs for 4 weeks, over-the-counter drugs for 2
weeks, and caffeine and alcohol for 72 hours. All participants
were homogenous CYP2C19 EM genotype (∗1/∗1). They
were genotyped for the ABCB1, PON1, and CYP3A5 poly-
morphisms. Of all participants, 45% had clopidogrel HTPR.
Despite controlling the aforementioned factors, altogether
factors such as age, weight, sex, platelet count, haematocrit,
and genetic polymorphisms of ABCB1, PON1, and CYP3A5
explained only 18% of the clopidogrel active metabolite peak
plasma concentration (𝐶max) and the area under the plasma
concentration-time curve (AUC
𝑡
) variabilities. When 𝐶max
and AUC
𝑡
were added to these factors, they explained 48%
of pharmacodynamics variability. Noteworthily, the results
showed that there was no significant association between
the polymorphisms of ABCB1, PON1, and CYP3A5 and the
pharmacokinetics and pharmacodynamics of clopidogrel.
These findings indicated the burden of the unexplained
variability of clopidogrel response which consequently affects
the therapeutic outcome of patients. This unsolved mystery
can be due to unknown genetic polymorphisms or an inter-
action between several genetic polymorphisms and other
nongenetic factors.
Personalized therapy is the use of person’s genetics,
proteomics, and environmental information to prevent, diag-
nose, and treat disease [87]. It aims to tailor patients therapy
based on their genetic and nongenetic information rather
than treating the whole population of a disease with the
same treatment [88]. Since the discovery of clopidogrel
variable platelets reactivity, it has been challenging to achieve
optimum personalization of DAPT therapy. However, this
optimum antiplatelet therapy could not be achieved without
perfect prediction of the therapeutic outcome.
6. Adoption of Pharmacogenetics
Biomarkers in Clinical Practice
The biomarker is a biological indicator of disease, physi-
ological state, clinical status, response to drug therapy, or
pathogenic process, which can be estimated and appraised for
its indicative accuracy [89]. Accordingly, genetic variability
which is associated with a biological status can be used as
an indicative biomarker of that status. Pharmacogenetics
biomarkers have been used to predict drug therapeutic out-
come and avoid adverse drug reaction (ADR) prior to drug
use. In 2008, the FDA issued table of valid pharmacogenetics
biomarkers which contains list of drugs that had FDA label
warning of pharmacogenetics testing prior to drug use and
this list is frequently updated [90]. As there are several genetic
factors whichmay interfere with clopidogrel variable platelets
reactivity, genotyping of these polymorphisms was evaluated
for clopidogrel outcome prediction [19, 34]. Apparently, the
literature was consistent in this regard. The CYP2C19 poly-
morphism predominates the effect of other genetic variants.
Thus, the FDA considered the CYP2C19 polymorphism valid
pharmacogenetics biomarker of clopidogrel efficacy [90].
Although there are consistent literature asserting the
association between clopidogrel HTPR and the CYP2C19∗2
and ∗3 LoF alleles, in depth analysis of the data indicated
that this association is strong in the PM who are carriers of
the homozygous genotypes of the CYP2C19 (∗2/∗2,∗3/∗3)
but not for the same extent with the IM who are carriers of
the heterozygous genotypes (∗1/∗2,∗1/∗3) [4, 91–93]. Fur-
thermore, patientswho are EMbut suffering from clopidogrel
HTPRwould bemisclassified as responsive (having optimum
clopidogrel platelets inhibition) based on their CYP2C19
genotype [94]. Nasyuhana Sani and colleagues studied the
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Clopidogrel variable platelets reactivity
Clinical factors
(i) Poor compliance
(ii) Underdosing
(iii) Poor absorption
(iv) Drug-drug interaction
(v) Acute coronary syndrome
(vi) Diabetes mellitus/insulin 
resistance
(vii) Elevated body mass Index
(viii) Smoking
Genetic factors
(i) Polymorphism of
(a) CYP isoforms
(d)GPIIB/IIIa
(e) CES1
(f) PON1
(b) P2Y12 receptor
(c) ABCB1
Cellular factors
(i) Accelerated platelet turnover
(ii) Reduced CYP metabolic activity
(iii) Increased ADP exposure
(iv) Upregulation of
(c) P2Y-independent pathways 
(collagen, epinephrine, 
thromboxane A2, thrombin)
(a) P2Y12 pathway
(b) P2Y1 pathway
Figure 1: The genetic and nongenetic factors which may contribute to clopidogrel variable platelets reactivity. The figure presents the known
genetic and nongenetic factors (cellular and clinical factors) whichmay contribute to clopidogrel variable platelets reactivity.CYP: cytochrome
P450, ADP: adenosine diphosphate, GPIIB/IIIa: Glycoprotein IIB/IIIa, ABCB1: ATP-Binding Cassette Subfamily B Member 1. This figure is
adapted and modified with permission from the publisher. Original source: Angiolillo and Ferreiro (2010) [85]. Copyright© (2010) Sociedad
Espan˜ola de Cardiologı´a. Published by Elsevier Espan˜a SL. All rights reserved.
effect ofCYP2C19 genotype on clopidogrel platelets reactivity
among healthy volunteers from three East Asian ethnicities
[92]. They had found that although carriers of one or two
alleles of the CYP2C19∗2 had significantly low platelets
inhibition while on clopidogrel, low platelets inhibition was
found in wild type homozygous carriers CYP2C19 (∗1/∗1) as
well. Similarly, Mejin and colleagues had found that there
was no significant association between clopidogrel HTPR
and CYP2C19 genotype among Malaysian CAD patients
[93]. A systematic review and meta-analysis had concluded
that, with the exception of stent thrombosis, the CYP2C19
genotype is not significantly associated with cardiovascular
events, despite its association with platelets aggregation [95].
Simply put, this can be merely justified by several facts.
The CYP2C19∗2 allele contributes to 12% of clopidogrel
variable platelets reactivity which means great portion of
this variability remains unpredicted by the genotype [19, 96].
The total activity of the CYP2C19 enzyme is affected not
only by the genotype but also by the interacting inducer and
inhibitor drugs [97]. In other words, some EM subjects may
experience poor metabolizing activity of the CYP2C19 due
to concomitant administration of inhibitor drugs and vice
versa; the PM subjects taking concomitant inducer drugsmay
experience normal metabolizing activity of the CYP2C19.
Besides, although it might be with considerably minimal
effect, the synergetic effect of other genetic variabilities such
as the PON1, the CYP3A4/5, the ABCB1, the P2Y12 receptors,
and the CES1 cannot be neglected [20, 22–24, 40]. Indeed,
it is expensive and less practical to genotype all the sus-
pected clopidogrel related genetic variabilities. In addition,
the limited role of genetic testing could be due to the fact
that most of genetic mutations have inadequate prediction
of the outcome [98]. As early mentioned, in the study of
Frelinger et al. (2013), the known nongenetic and genetic
factors explained 18% of the clopidogrel pharmacokinetics
(PK) and 32%–65% of clopidogrel pharmacodynamics (PD).
This means great portion of clopidogrel HTPR cannot be
identified by CYP2C19 genotyping. Therefore, the Clinical
Pharmacogenetics Implementation Consortium Guidelines
for CYP2C19 genotype and Clopidogrel Therapy (CPIC), in
its update (2013), did not recommend the CYP2C19 guided
therapy for all patients [10].
7. Pharmacokinetics Assessment
of Clopidogrel Response
Several studies had evaluated different pharmacokinetics
(PK)methods to determine the level of the parent compound
clopidogrel and its metabolites as an indicator of clopidogrel
platelets inhibition [5, 99, 100]. It was found that the level of
clopidogrel active metabolite is correlated with clopidogrel
platelets inhibition [86, 101], and the PK of clopidogrel
could be predicted by the CYP2C19 genotype [102]. However,
applying PK to assess clopidogrel response is limited by
several factors. The active thiol metabolite of clopidogrel is
not stable which requires adding stabilizing agent within 30
seconds of blood sampling [101]. Some studies used indirect
quantification of the active metabolite by quantifying the
parent compound and the inactive metabolite [99, 103].
This means an accurate quantification of the active thiol
metabolite in blood is difficult. Furthermore, the plasma level
of the active metabolite of clopidogrel may not reflect the
response in subjects affected by P2Y12 receptor polymor-
phism, receptor density, fibrinogen, platelets concentration,
and accelerated turnover of platelets variabilities [86, 104].
Therefore, the PK assessment can estimate the level of the
parent compound and the active metabolite but it may not
be optimum method to personalize clopidogrel antiplatelet
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therapy unless it is done together with other approaches such
as pharmacogenetics or platelets function testing (PFT) to
provide further information that can help to individualize the
therapy.
8. Implementation of Platelets
Function Testing (PFT) to Personalize
Clopidogrel Therapy
Due to the limited prediction power of the pharmacogenetics
biomarkers of clopidogrel platelets inhibition, the suggestion
to personalize antiplatelet therapy based on platelets function
testing (PFT) gained attraction. This had increased the
demand to evaluate the use of PFT assays in the assessment of
clopidogrel therapeutic outcome. PFT is one of the important
methods to assess the effect of antiplatelet drugs and platelets
defects.The PFT assessment of antiplatelet drugs relies on the
measurement of platelets inhibition which happened due to
the effect of the drug. There are different PFT instruments
which are widely used to assess antiplatelet drugs such as
the optical light transmission aggregometry (LTA) [105],
the VerifyNow system (VN) (Accumetrics Inc., San Diego,
California) [106], the vasodilator stimulated phosphoprotein
phosphorylation assay (VASP-P) [107, 108], the multiple
electrode platelet aggregometry (MEA) [105], the platelets
function analyser (PFA-100) [109–111], the Impact-R assay
[110], and the platelet-works (PW) [110]. The PFT instru-
ments have different techniques, agonist reagents, and testing
kits to test different classes of antiplatelet drugs [105, 109].The
PFT agonist reagent induces platelets activation in the sample
through stimulation of the drug target.The aggregation of the
platelets will be measured by the instrument and it indicates
the status of platelets activity after the effect of the drug.
Table 2, compares some of the available PFT instruments.
For each PFT instrument, there is a specified kit or agonist
reagent to test clopidogrel response; it mainly contains ADP
as stimulant of P2Y12 receptors. The LTA is the gold stan-
dard PFT assay [109]. However, the VASP-P assay is highly
specific to P2Y12 receptor. Therefore, it is often considered
the gold standard PFT assay for P2Y12 inhibitors. Several
studies evaluated the ability of PFT assays to predict major
cardiac events after PCI [112, 113]. However, the “Do Platelet
Function Assays Predict Clinical Outcome in Clopidogrel-
Pretreated PatientsUndergoing Elective PCI” (Popular) study
had compared the predictability of five different PFT assays
[114].The PFT assays were the LTA, VN, IMPACT-R, PW, and
PFA-100.The study concluded that LTA, VN, and PW are the
best PFT assessment predictors of atherothrombotic events
including stent thrombosis, despite the limitation of low
power in predicting bleeding risk. Generally, the use of PFT to
tailor clopidogrel therapy has its limitations. The researchers
from the “Double Randomization of a Monitoring Adjusted
Antiplatelet Treatment versus a Common Antiplatelet Treat-
ment for DES Implantation, and Interruption versus Con-
tinuation of Double AntiplateletTherapy” (ARCTIC) clinical
trial had concluded that tailoring antiplatelet therapy based
onPFTdid not improve outcomes [115].This can be explained
by several confounding factors. For many of PFT assays,
the results are interfered by age, gender, ethnicities, diet,
platelets count, and haematocrit which lowers their accuracy
[109, 110, 116–118]. The results of PFT instruments which
utilize platelets aggregation technique for measurement are
highly affected by concomitant use of other antiplatelet drugs
such as GPIIb-IIIa antagonists [119]. In fact, the simulation
nature of PFT by using agonist in an in vitro setting to
stimulate platelets activation does not perfectly resemble the
physiological process of platelets activation which is affected
by many internal pathways [108]. This may lead to PFT
results that do not reflect the actual platelets function of the
patients. Although the LTAandVASP-P assays are considered
gold standard methods to measure platelets function, they
are not advocated in clinical practice because they are time
consuming and require lab facility and expert handling [120].
On the other hand, the VN-P2Y12 assay and other automated
point of care (POC) PFT assays are fast and easy, but they
are considerably expensive which limits the routine use of
them. Platelets reactivity changes overtime in clopidogrel
treated patients which necessitates frequent measurements
for precise PFT based personalized therapy [121]. Moreover,
there is inconsistency in the identification of clopidogrel
responsiveness when the prespecified cut-off points of PFT
assays were compared. In a study aimed to evaluate the
agreement on clopidogrel HTPR identification between three
PFT assays, the LTA, the VASP-P, and the VN-P2Y12, a
reduced agreement was reported between the three assays.
However, when the PFT results were tested for correlation
as continuous variables, there was correlation between the
results [122]. This implied that identifying clopidogrel HTPR
based on one PFT assay is not enough and may lead to
imperfect therapeutic decision. This might be one of the
factors that hinders tailoring antiplatelet therapy based on
PFT.
9. The Role of Systems Biology in
Personalized Medicine
Systems biology is the study of the biochemical, molecular,
and supramolecular networks, along with their connections
and interactions with the environmental factors in order
to investigate an intricate biological perturbation of the
living organism [123]. This term is an integrative approach
which investigates not only the biological “Omics” such as
genomics, transcriptomics, proteomics, and metabolomics,
but also the environmental factors such as nutrition, gut
microbiota, infections, other drugs, disease state, rest, and
sleep which interfere with them. In fact, the conventional
biology describes the biological processes in the living sys-
tem without considering the connections and interactions
between them and their environment; however, systems
biology is comprehensive in terms of explaining the biological
processes, their pathways networks, and other environmental
factors which all together contribute to a phenotype such as
disease or clinical trait [124, 125]. This will give an extensive
understanding of that phenotype by using the multidisci-
plinary “Omics” data as biomarkers of the phenotype [125].
While the study of the genes and their association with the
phenotype is the main interest of genomics, the study of
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Table 2: Platelets function testing devices.
PFT device Specimen PFT technique Laboratory requirement/point ofcare (POC)
Agonist
reagents/Cartridges
Light transmission
aggregometry (LTA) [105]
Platelet rich
plasma (PRP)
Optical light transmission
aggregometry
Requiring trained lab staff and
laboratory facility to do the test
ADP, arachidonic
acid, epinephrine
Multiple electrode platelet
aggregometry (MEA) [105] Whole blood Impedance aggregometry Semiautomated
ADP, arachidonic
acid, collagen
VerifyNow system (VN)
[106] Whole blood
Optical light transmission
aggregometry Fully automated, POC
P2Y12 kit
Aspirin kit
GP IIb/IIIa kit
Platelets function analyser
(PFA-100) [109–111] Whole blood
High shear force dynamic flow
system Semiautomated, POC
Collagen with ADP
Collagen with
epinephrine
Impact-R [110] Whole blood Shear stress platelet adhesion
Requiring trained lab staff and
laboratory facility to do the test.
Extensive sample handling is
needed
ADP
Vasodilator-stimulated
phosphoprotein
phosphorylation assay
using flow cytometry
(VASP-P) [107, 108]
Whole blood
Flow cytometric fluorescent
quantification of intraplatelet
VASP
Requiring trained lab staff,
intensive lab work, sample
preparation
VASP-P2Y12 assay
Platelet works (PW) [110] Whole blood Single platelet count Semiautomated ADP
POC: point of care, ADP: adenosine diphosphate, GP IIb/IIIa: glycoprotein IIb/IIIa, and VASP-P: vasodilator-stimulated phosphoprotein phosphorylation.
P2Y12 kit: VerifyNow kit designed to test the P2Y12 receptor blockade to assess the response to P2Y12 inhibitors. Aspirin kit: VerifyNow kit designed to test the
response to aspirin via arachidonic acid initiated reaction. GP IIb/IIIa kit: VerifyNow kit designed to test the response to GP IIb/IIIa inhibitors. VASP/P2Y12
assay: VASP phosphorylation correlates with the P2Y12 receptor inhibition.
the messenger ribonucleic acid (mRNA) and transcription
process is the aim of transcriptomics [126]. The proteomics
focuses on peptides and proteins expression [127]. Eventually,
as all the substrates in the organism will be subjected to
metabolism, the metabolomics focuses on the study of the
metabolites [128]. The role of systems biology in the predic-
tion of the phenotype and the personalization of therapy is
shown in Figure 2.
Apart from pharmacogenomics biomarkers which had
been extensively studied, there is scant data on the use of
other systems biology approaches such as transcriptomics,
proteomics, and metabolomics to find novel biomarkers of
clopidogrel variable platelets reactivity and cardiovascular
outcome. In a proteomics approach, Caruso et al., 2015,
were the first to report an investigation of platelets pro-
teomes after 24 hours of clopidogrel loading dose in 12
ACS patients (6 responders and 6 nonresponders). They
indicated significant upregulation of the platelet adhesion
molecule cluster differentiation-226 (CD226), downregula-
tion of peroxiredoxin-4, and increased expression of trans-
ferrin in patients suffering from clopidogrel HTPR [129]. To
the best of our literature review, there is no study which had
investigated the use of metabolomics to assess clopidogrel
response.
10. Disease and Drug Response
Phenotyping Using Metabolomics
Metabolomics (metabonomics in some literature) is the study
of the metabolites of the living organisms’ metabolome [130].
Themetabolites are the ultimate small molecules compounds
which are outcomes of the metabolism of the systems biology
components and the environmental factors interfering with
it [131]. The metabolome of each living system varies with
the variations in the systems biology components and the
various environmental factors affecting it [130]. Accordingly,
the metabolomes of subjects having particular phenotype
(disease condition or drug response) cluster in discrimina-
tory way from their controls upon analysing the metabolome
of their biological samples [132]. This differentiation usually
happens due to the presence of discriminating metabolites in
the metabolome which is termed the metabolic fingerprint
or metabotype [133]. The identified metabotype can be used
as a biomarker of the phenotype. The metabolomics analysis
involves analysing biological samples such as urine, serum,
plasma, exhaled breath, sputum, cerebrospinal fluids (CSF),
and cell culture using spectroscopic instruments such as
nuclear magnetic resonance (NMR) or mass spectroscopy
(MS) to identify and quantify the metabolites in the sam-
ple [134–136]. Metabolomics approach has been used in
several studies to find novel biomarkers of diseases. It
was used to identify new biomarkers of asthma, chronic
obstructive pulmonary disease (COPD), cancer, and other
diseases [135, 137, 138]. The use of metabolomics approach
to explore and understand different cardiac conditions has
been evolved. In an animal model of rats harbouring human
renin and angiotensinogen genes, Mervaala and colleagues
used metabolomics to test whether angiotensin II alters the
metabolic profile of the heart [139]. They concluded that
angiotensin II plays key role in the metabolic profile of the
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Figure 2: The role of Systems Biology in Personalized Medicine. The figure elucidates how all “Omics” disciplines can provide phenotype
biomarkers (disease or drug response biomarkers). Together with patient medical history and current clinical data, these biomarkers can help
to personalize patient’s therapy.Themetabolomics is the ultimate “Omics” that is close to the phenotype, as well as reflecting the perturbation
in other “Omics.” This figure is adapted and modified with permission from the publisher. Original source: Louridas and Lourida (2012).
Published by Hippokratia. All rights reserved [125].
heart. Tenori and colleagues investigated the use of NMR
profiling of serum and urine to find a metabolic finger print
associated with heart failure (HF) and its relationship with
New York Heart Association (NYHA) functional classes in
humans [140]. The NMR analysis of serum and urine sig-
nificantly discriminated HF patients from their healthy con-
trols with high accuracy (greater than 86%). However, it was
not able to discriminate patients among the NYHA classes of
HF.
11. Pharmacometabolomics
Pharmacometabolomics or pharmacometabonomics in some
literature is a metabolomics analysis which aims to discover
novel biomarkers in the metabolome that predict drug res-
ponse or toxicity [141, 142]. These novel biomarkers can be
used as classifying tool to classify patients to responsive
and nonresponsive to drug or may develop and may not
develop drug toxicity [143]. Drug response metabotype not
only predicts patient’s response but also explains response
related pathways and monitor patient’s outcome during
disease management which will improve the personalization
of therapy [136, 143, 144]. The term was first proposed
by Clayton et al., 2006. They analysed urine samples of
rat pre-dose and postdose of 600mg of paracetamol using
proton nuclear magnetic resonance (1H-NMR) spectroscopy
to find metabotype which is associated with paracetamol
induced hepatotoxicity [145]. It was revealed that high level
of predose taurine was associated with low liver damage
assessed by mean histology score (MHS) [145]. However,
predose low levels of trimethylamine-N-oxide (TMAO) and
betaine were associated with increased paracetamol induced
liver damage. A repeat of the study in healthy volunteers
indicated that high level of predose urinary p-cresol sul-
fate was associated with low postdose urinary ratios of
acetaminophen sulfate to acetaminophen glucoronate (S/G)
which is due to the competence between acetaminophen and
p-cresol on sulfotransferase enzyme [144]. Thus, the high
level of endogenous p-cresol causes an increase in liver amen-
ability for acetaminophen hepatotoxicity and its urine sulfate
form can be used as predose predictive biomarker of it. The
pharmacometabolomics studies have been evolved in using
different biofluids samples to find metabotypes of drug
efficacy and toxicity [136, 146–149]. In Table 3, the findings
of some pharmacometabolomics studies in humans are sum-
marized.
11.1. Pharmacometabolomics Spectroscopic Techniques. There
are many spectroscopic methods commonly used in meta-
bolomics/pharmacometabolomics studies such as nuclear
magnetic resonance (NMR) or 1H-NMR, MS combined with
gas or liquid chromatographic extraction (GC, LC) and
Fourier transform infrared spectroscopy (FT-IR) [150–152].
Among them, 1H-NMR and MS are widely used [153]. Each
of them has its advantages and limitations. The selection of
the suitable spectroscopic method in a study depends on the
features of each method and the compatibility of the method
with the study’s aim. The GC or LC combined MS method is
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Table 3: Examples of pharmacometabolomics studies in humans.
Study Drug Analytical method Specimen Main findings
Holmes et al., 2006
[136]
Antipsychotic
drugs∗
1HNMR CSF
A metabotype of schizophrenia which discriminated antipsychotic
drug naive patients from healthy control. This metabotype was
alleviated in half of the patients to normal after short term treatment
with antipsychotic drugs.
Kim et al., 2010
[146]
Cyclosporine A
(CsA) &
Tacrolimus
(TAC)
1HNMR Serum
Time dependent metabolites changes in response to different
treatment. The difference in the level of trimethylamine-N-oxide
(TMAO) which is associated with graft dysfunction, between 2
groups of immunosuppressant drugs treatment; CsA & TAC were not
significant. Lipid metabolites were higher in CsA group increasing the
risk of cardiovascular diseases.
Wang et al., 2012
[147] Methotrexate
1HNMR Serum
Identification of 11 metabolites which can discriminate between
methotrexate efficacy groups in patients with early rheumatoid
arthritis.
Kaddurah-Daouk
et al., 2013 [148] Sertraline GC-TOF-MS Serum
Discriminating metabotypes of symptoms reduction between
sertraline and placebo in MDD patients on one week and 4 weeks of
treatment. Symptoms reduction after one week of sertraline treatment
was associated with the reduction of 5-methoxytryptamine levels,
while it was associated with lower levels of branched chain amino
acids at four weeks of sertraline treatment.
Yerges-Armstrong
et al., 2013 [164] Aspirin GC-MS Serum
Identification of aspirin exposure metabotype of 18 metabolites in
healthy volunteers who were on aspirin 81mg for 14 days (HAPI
study). Aspirin exposure metabotype was significantly associated
with purine metabolic pathway. Inosine and adenosine were
significantly higher after aspirin in aspirin HTPR group.
Villasen˜or et al.,
2014 [149] Ketamine LC-QTOF-MS Plasma
Identification of discriminating metabolites between responders and
nonresponders of ketamine among bipolar depression patients. The
discriminating metabolites were related to mitochondrial 𝛽-oxidation
of fatty acid.
Ellero-Simatos et
al., 2014 [166] Aspirin LC-MS Serum
Elevated level of baseline serum serotonin is associated with aspirin
HTPR based on collagen induced PFT assessment of healthy subjects
who were on aspirin 81mg for 14 days (HAPI study).
1HNMR: proton nuclear magnetic resonance, GC: gas chromatography, TOF: time of flight, MS: mass spectroscopy, QTOF: quadrupole time of flight, LC:
liquid chromatography, CSF: cerebrospinal fluid, CVDs: cardiovascular diseases, CsA: Cyclosporine A, TAC: Tacrolimus, TMAO: trimethylamine-N-oxide,
MDD: major depressive disorder, HAPI: Heredity and Phenotype Intervention, and HTPR: high on treatment platelets reactivity.
∗Antipsychotic drugs: atypical antipsychotic drug such as amisulpride, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone.
more sensitive than 1H-NMR; thus it is highly recommended
for metabolomics studies where particular group of com-
pounds is being targeted such as lipid compounds [152, 154].
However, as it requires prior separation using LC or GC,
it is time consuming and necessitates more lab work [145].
The 1H-NMR method is fast and does not require extensive
sample processing [155]. Besides, prepared 1H-NMR samples
can be run in large quantities with automated bulk run of
samples [156, 157]. Samples prepared for 1H-NMR analysis
can be stored and rerun for further analysis. Therefore, it
is preferred choice for untargeted metabolomics analysis of
large number of patients’ samples.
11.2. Pharmacometabolomics Data Analysis. Pharmacometa-
bolomics data analysis relies on prediction modelling using
chemometrics analysis [158].This includes multivariate anal-
ysis through the use of unsupervised and supervisedmachine
learning methods [159]. The commonly used unsupervised
method inmetabolomics is the principal component analysis
(PCA), while the supervised methods include methods such
as partial least square (PLS), discriminant function analysis
(DFA), and artificial neural networks (ANNs). The PCA
provides an overview screening for the systematic variation
of the data regardless of prior classification. Thus, it is
exploratory analysis and usually followed by the supervised
analysis where a prior input classification is introduced. The
identification and pathway interpretation of the metabo-
lites include combining knowledge in the pathophysiol-
ogy of the phenotype with the analytical chemistry of the
potential compound [160]. There are available databases
which can be used to identify the putative biomarkers in
metabolomics analysis such asHumanMetabolomeDatabase
(HMDB), the Chenomx (Chenomx Inc., Canada), the
MetaboLights, the Birmingham Metabolite Library (BML-
NMR), and the Biological Magnetic Resonance Data Bank
(BMRB-metabolomics).
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12. Pharmacometabolomics Informs
Pharmacogenomics
The “pharmacometabolomics informs pharmacogenomics”
approach implies that pharmacometabolomics can be used
to identify genetic variation which is associated with the
variation of drug response or toxicity [161]. Simply put, this
concept is based on the fact that the variation in genes or
genes’ expression may lead to variations in proteins and
eventually the metabolites levels which are associated with
these pathways will change [162]. Accordingly, a metabotype
which is associated with drug response may contain some
metabolites associated with the variations in genes or genes
expression which are implicated in the variable response. Ji
and colleagues were the first to elucidate this concept on the
variable response to the selective serotonin reuptake inhibitor
(SSRI) escitalopram [163]. From major depressive disorder
(MDD) patients on escitalopram whom were included in the
Myo-PGRN SSRI study, 20 responders and 20 nonresponders
were recruited for plasma pharmacometabolomics analysis.
Baseline glycine levels were significantly different (𝑃 = 0.005)
between the two groups and had negative associationwith the
treatment outcome (remission) [163].The researchers studied
the glycine biosynthesis and metabolism to assign SNPs
which are possibly related to these pathways. The selected
SNPs were genotyped using the DNA of 512 patients from
the same study (Myo-PGRN SSRI). Of the 135 assigned SNPs,
the rs10975641 SNP from the glycine dehydrogenase gene
was associated with response and remission. Similarly, using
the same approach novel genetic variability associated with
aspirin HTPR was discovered [164, 165]. Yerges-Armstrong
et al. (2013) identified aspirin response metabotype in serum
samples of healthy volunteers from the Heredity and Pheno-
type Intervention (HAPI) Heart study [164]. Aspirin HTPR
group had significantly higher postaspirin levels of purine
metabolites: inosine and adenosine. Association analysis of
SNPs in the purine genes and aspirin HTPR led to the identi-
fication of the rs16931294 SNP in the adenosine kinase (ADK)
gene region. Aspirin HTPR was significantly associated with
the less common G allele rather than the more common A
allele of the rs16931294 (𝛽 = 0.8, 𝑃 = 0.00034). Furthermore,
the G allele was significantly associated with preaspirin levels
of adenosine monophosphate, hypoxanthine, and xanthine
and postaspirin levels of inosine and guanosine. Therefore,
pharmacometabolomics gained informationmay help to dis-
cover unknown genetic variations and response metabotypes
can be used as an economical tool to predict both the
response and the possible genetic cause of the response.
13. Conclusion
Clopidogrel had been well established as essential antiplatelet
therapy paired with aspirin in DAPT therapy. Due to its high
margin of safety, in terms of bleeding and side effects, and
its price, clopidogrel remains the preferred P2Y12 antagonists
in clinical practice. However, some patients fail to achieve
therapeutic outcome while on clopidogrel. Finding precise
method for predicting clopidogrel outcome is crucial to
guide antiplatelet therapy. Current methods, the CYP2C19
genotyping, PK, and PFT, have their drawbacks. Investigat-
ing other systems biology approaches such as proteomics
and metabolomics may be the preeminence for clopidogrel
personalization. Pharmacometabolomics approach has been
used in assessing drug response, as well as identifying
novel genetic variations associated with the response. As the
perturbation in the metabolome is close to the phenotype,
it can be highly reflective of drug’s variable response. To
date, pharmacometabolomics had never been evaluated in
personalizing clopidogrel therapy. An integration of phar-
macometabolomics and pharmacogenomics may not only
tailor the therapy but also provide better understanding of the
mystery behind clopidogrel HTPR.
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